CVS Health trades at an 11x forward P/E despite a strong Q2 earnings beat and raised 2026 guidance, leaving significant upside potential if Aetna's margin recovery proves durable against looming PBM regulatory risks.
CVS raised 2026 EPS guidance and beat Q2 estimates, driving bullish analyst revisions, though PBM regulation risks remain.
CVS Health shares currently trade near $94, reflecting a significant discount to analyst price targets and internal valuation models. Management recently raised 2026 adjusted EPS guidance to $7.90–$8.10, supported by a strong Q2 earnings beat and improved margins at Aetna. While analyst sentiment remains overwhelmingly positive, the stock's future performance hinges on the durability of Aetna's recovery and potential regulatory headwinds facing its PBM business.
The gap reflects market skepticism regarding whether the company's forward earnings growth is sustainable, specifically concerning PBM regulatory risks and the durability of Aetna's margin improvements.
Key risks include potential PBM re-regulation, legislative intervention in GLP-1 and drug pricing, and the possibility that recent guidance increases represent a cyclical peak rather than a long-term growth launchpad.